Enalapril Hydrochlorothiazide Tablets

There are no relevant research results yet.

This product is a compound preparation, the components of which are (1) enalapril maleate: 1-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-L-proline 1'-ethyl ester maleate (1:1); (2) hydrochlorothiazide: 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide.

This product is a film-coated tablet, which appears white after removing the film.

This product is only suitable for patients whose blood pressure cannot be effectively controlled by single drug therapy and who need combined drug therapy. This product is not suitable for initial treatment.

Oral administration, 1-2 tablets at a time, once a day; or as directed by your doctor.

1. Common symptoms include: dizziness, headache, fatigue, cough, all mild and short-lived. 2. Less common symptoms include: muscle cramps, nausea, weakness, orthostatic discomfort, impotence, diarrhea. 3. Rare symptoms include: syncope, hypotension, orthostatic hypotension, palpitations, tachycardia; vomiting, indigestion, dry mouth, constipation, insomnia, nervousness, paresthesia; rash, itching; rarely, angioedema, which can be fatal if it occurs in the throat. If angioedema occurs, this product should be discontinued immediately and treated quickly, with 0.3-0.5 ml of 1:1000 epinephrine injection subcutaneously.

This product is contraindicated for patients who are allergic to any component of this product, who have previously developed angioedema after treatment with certain angiotensin-converting enzyme inhibitors, and who have a history of hereditary and idiopathic angioedema. Due to the presence of hydrochlorothiazide, this product is contraindicated for patients with anuria or allergy to sulfonamides. This product is contraindicated for patients with severe renal insufficiency.

Precautions for children: Not clear yet. Precautions for pregnancy and lactation: This product can pass the placenta. Neonatal hypotension, renal failure, skull dysplasia, or death have been reported in patients taking enalapril in the second and third trimesters of pregnancy. Oligohydramnios can also occur, so it is contraindicated for pregnant women. This product can be excreted into breast milk, so it is not recommended for lactating women. Precautions for the elderly: In clinical studies of the combination of enalapril and hydrochlorothiazide, the efficacy and tolerability of elderly and young hypertensive patients were similar, but elderly patients should closely observe blood pressure changes when using this product, and the initial dose should be small, and the dose should be adjusted according to the condition.

1. When used in combination with non-depolarizing skeletal muscle relaxants (such as tubocurarine), the effect of muscle relaxants may be enhanced. 2. When enalapril maleate is used in combination with potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes, it may lead to increased blood potassium, while hydrochlorothiazide reduces blood potassium. 3. When enalapril maleate is used in combination with lithium preparations, the serum lithium concentration increases; hydrochlorothiazide reduces the renal clearance rate of lithium and greatly increases the risk of lithium poisoning. Therefore, when this product is used in combination with lithium preparations, the blood lithium concentration needs to be checked to avoid hyperlithiasis. 4. Non-steroidal anti-inflammatory drugs can reduce the antihypertensive effect of diuretics. When used in combination with this product, blood pressure changes should be observed. 5. When hydrochlorothiazide is used in combination with hypoglycemic drugs, the dosage of hypoglycemic drugs should be adjusted.

Seal and store in a dry place.

Each tablet contains 10 mg of enalapril maleate and 6.25 mg of hydrochlorothiazide.

24 months

Beijing Honglin Pharmaceutical Co., Ltd.

• Founded in:

  1993-12-07

• Address:

  Yanqi Industrial Development Zone, Huairou District, Beijing

• Tax NO.:

  91110000621702873B

• Registered Funds:

  $15.8 million

• Website:

  Log in to view

• Email:

  Log in to view